|
Volumn 65, Issue 6, 2001, Pages 685-689
|
Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi
a a a a a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
PRIMAQUINE;
SITAMAQUINE;
ABDOMINAL DISCOMFORT;
ADOLESCENT;
ADULT;
ARTICLE;
BRAZIL;
CHILD;
CLINICAL FEATURE;
CLINICAL TRIAL;
DRUG EFFICACY;
DRUG SAFETY;
FEMALE;
HEADACHE;
HUMAN;
KENYA;
LEISHMANIA CHAGASI;
LEISHMANIASIS;
MALE;
METHEMOGLOBINEMIA;
NEPHROTOXICITY;
PHASE 2 CLINICAL TRIAL;
TREATMENT OUTCOME;
VISCERAL LEISHMANIASIS;
ANIMALIA;
LEISHMANIA DONOVANI CHAGASI;
NASO HEXACANTHUS;
PROTOZOA;
|
EID: 0035687445
PISSN: 00029637
EISSN: None
Source Type: Journal
DOI: 10.4269/ajtmh.2001.65.685 Document Type: Article |
Times cited : (112)
|
References (16)
|